EC approves Keytruda® (pembrolizumab) for the treatment of renal cell carcinoma

Jan 27, 2022

MSD announced that the EC has approved Keytruda® (pembrolizumab) for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Print Page Mail Article